Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

COVID-19

Cancer therapy tool informs COVID-19 vaccines

Subjects

T cell vaccines against SARS-CoV-2 are being developed at a rapid pace, but it is imperative that the proteins or peptides they deliver bind to a large variety of HLA haplotypes in the global population. Using a computational tool designed to predict candidate neoantigens for cancer vaccines, this preprint identifies 1,103 unique 9-mer antigens from the SARS-CoV-2 peptidome, each of which binds to a median of 3 of 1,022 HLA class I alleles. This resulted in 6,748 peptide–MHC pairs with high binding affinity. Up to 684 peptides were derived from each viral protein tested. Furthermore, 12 of the identified SARS-CoV-2 epitopes match SARS-CoV epitopes that were previously shown to generate T cell responses ex vivo and in vitro. This publicly available dataset will be an important resource to guide vaccine development.

References

Original article

  1. Campbell, K. M. et al. Prediction of SARS-CoV-2 epitopes across 9360 HLA class I alleles. Preprint at bioRxiv https://doi.org/10.1101/2020.03.30.016931 (2020)

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Miriam Saffern.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Saffern, M. Cancer therapy tool informs COVID-19 vaccines. Nat Rev Immunol 20, 352 (2020). https://doi.org/10.1038/s41577-020-0326-1

Download citation

Search

Quick links